title: Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases.
abstract: Adult T cell leukemia / lymphoma (ATL) is one of the most aggressive hematological malignancies caused by human T-lymphotropic virus type-I (HTLV-1). Mogamulizumab is a new defucosylated humanized monoclonal antibody agent which targets C-C chemokine receptor type 4 (CCR4) expressed occasionally on the surface of ATL cells. However, adverse events such as drug eruptions have also been highlighted, at least in part, via the dysfunction of regulatory T cells (Tregs). We herein report a pronounced recurrence of systemic psoriasis vulgaris accompanied by the treatment of mogamulizumab in a patient with ATL. Pathological examinations may suggest a mechanistic link between the recurrence of autoinflammatory diseases and anti-CCR4 antibody therapies.
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan.
authors.forename: Kazuho
authors.initials: K
authors.lastname: Morichika
authors.forename: Takeaki
authors.initials: T
authors.lastname: Tomoyose
authors.forename: Taeko
authors.initials: T
authors.lastname: Hanashiro
authors.forename: Natsuki
authors.initials: N
authors.lastname: Shimabukuro
authors.forename: Keita
authors.initials: K
authors.lastname: Tamaki
authors.forename: Iori
authors.initials: I
authors.lastname: Tedokon
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Nishi
authors.forename: Sawako
authors.initials: S
authors.lastname: Nakachi
authors.forename: Ken-Nosuke
authors.initials: KN
authors.lastname: Karube
authors.forename: Takuya
authors.initials: T
authors.lastname: Fukushima
authors.forename: Takeharu
authors.initials: T
authors.lastname: Katoh
authors.forename: Koichi
authors.initials: K
authors.lastname: Ohshima
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Masuzaki
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D015368:Human T-lymphotropic virus 1 / Q000276:immunology; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000628:therapy; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced*; D012008:Recurrence
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C549035:mogamulizumab